Neuroinflammation as a Novel Target to Treat Bipolar Depression: A Pilot PET Study with 11CPBR-28 and an Experimental Medication: ethyl EPA
Brain imaging in bipolar depression to understand the role of inflammation in its treatment.
Sponsor: Columbia University Irving Institute
Enrolling: Male and Female Patients
IRB Number: 8044
Contact: Martin Lan: 646-774-7610 /
Additional Study Information: This is a research study to understand what causes bipolar disorder and how medications treat bipolar depression. Particularly, we are looking at the importance of inflammation in the process. If you participate, you will receive an experimental medication for your depression named ethyl eicosapentaenoic acid (ethyl EPA), an omega 3 fatty acid. You will also have genetic testing and three different brain scans (one MRI and two PET scans). The study is funded by the Columbia University Irving Institute to improve the treatment of bipolar disorder. Please contact us if you are interested in participating.
This study is closed
Martin Lan, MD
Do You Qualify?
Do you have a diagnosis of bipolar disorder? Yes No
Are you currently having symptoms of depression? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Martin Lan